376 related articles for article (PubMed ID: 32118336)
21. Immunogenicity of a subunit vaccine against Bacillus anthracis.
Chichester JA; Musiychuk K; de la Rosa P; Horsey A; Stevenson N; Ugulava N; Rabindran S; Palmer GA; Mett V; Yusibov V
Vaccine; 2007 Apr; 25(16):3111-4. PubMed ID: 17280756
[TBL] [Abstract][Full Text] [Related]
22. Protective effect of Bacillus anthracis surface protein EA1 against anthrax in mice.
Uchida M; Harada T; Enkhtuya J; Kusumoto A; Kobayashi Y; Chiba S; Shyaka A; Kawamoto K
Biochem Biophys Res Commun; 2012 May; 421(2):323-8. PubMed ID: 22507985
[TBL] [Abstract][Full Text] [Related]
23. Killed but metabolically active Bacillus anthracis vaccines induce broad and protective immunity against anthrax.
Skoble J; Beaber JW; Gao Y; Lovchik JA; Sower LE; Liu W; Luckett W; Peterson JW; Calendar R; Portnoy DA; Lyons CR; Dubensky TW
Infect Immun; 2009 Apr; 77(4):1649-63. PubMed ID: 19168734
[TBL] [Abstract][Full Text] [Related]
24. Generation of protective immune response against anthrax by oral immunization with protective antigen plant-based vaccine.
Gorantala J; Grover S; Rahi A; Chaudhary P; Rajwanshi R; Sarin NB; Bhatnagar R
J Biotechnol; 2014 Apr; 176():1-10. PubMed ID: 24548460
[TBL] [Abstract][Full Text] [Related]
25. Effect of nasal immunization with protective antigen of Bacillus anthracis on protective immune response against anthrax toxin.
Gaur R; Gupta PK; Banerjea AC; Singh Y
Vaccine; 2002 Jun; 20(21-22):2836-9. PubMed ID: 12034111
[TBL] [Abstract][Full Text] [Related]
26. Towards a human oral vaccine for anthrax: the utility of a Salmonella Typhi Ty21a-based prime-boost immunization strategy.
Baillie LW; Rodriguez AL; Moore S; Atkins HS; Feng C; Nataro JP; Pasetti MF
Vaccine; 2008 Nov; 26(48):6083-91. PubMed ID: 18805452
[TBL] [Abstract][Full Text] [Related]
27. Contribution of immunological memory to protective immunity conferred by a Bacillus anthracis protective antigen-based vaccine.
Marcus H; Danieli R; Epstein E; Velan B; Shafferman A; Reuveny S
Infect Immun; 2004 Jun; 72(6):3471-7. PubMed ID: 15155654
[TBL] [Abstract][Full Text] [Related]
28. Protection of mice against challenge with Bacillus anthracis STI spores after DNA vaccination.
Hahn UK; Alex M; Czerny CP; Böhm R; Beyer W
Int J Med Microbiol; 2004 Jul; 294(1):35-44. PubMed ID: 15293452
[TBL] [Abstract][Full Text] [Related]
29. Anthrax protective antigen delivered by Salmonella enterica serovar Typhi Ty21a protects mice from a lethal anthrax spore challenge.
Osorio M; Wu Y; Singh S; Merkel TJ; Bhattacharyya S; Blake MS; Kopecko DJ
Infect Immun; 2009 Apr; 77(4):1475-82. PubMed ID: 19179420
[TBL] [Abstract][Full Text] [Related]
30. Characterisation of the immune response to the UK human anthrax vaccine.
Baillie L; Hebdon R; Flick-Smith H; Williamson D
FEMS Immunol Med Microbiol; 2003 May; 36(1-2):83-6. PubMed ID: 12727370
[TBL] [Abstract][Full Text] [Related]
31. Plasmid-based vaccination with candidate anthrax vaccine antigens induces durable type 1 and type 2 T-helper immune responses.
Zhang Y; Qiu J; Zhou Y; Farhangfar F; Hester J; Lin AY; Decker WK
Vaccine; 2008 Jan; 26(5):614-22. PubMed ID: 18166249
[TBL] [Abstract][Full Text] [Related]
32. Nasal immunization with the mixture of PA63, LF, and a PGA conjugate induced strong antibody responses against all three antigens.
Sloat BR; Shaker DS; Le UM; Cui Z
FEMS Immunol Med Microbiol; 2008 Mar; 52(2):169-79. PubMed ID: 18194342
[TBL] [Abstract][Full Text] [Related]
33. Poly(gamma-D-glutamic acid) protein conjugates induce IgG antibodies in mice to the capsule of Bacillus anthracis: a potential addition to the anthrax vaccine.
Schneerson R; Kubler-Kielb J; Liu TY; Dai ZD; Leppla SH; Yergey A; Backlund P; Shiloach J; Majadly F; Robbins JB
Proc Natl Acad Sci U S A; 2003 Jul; 100(15):8945-50. PubMed ID: 12857944
[TBL] [Abstract][Full Text] [Related]
34. Rapid vaccination using an acetalated dextran microparticulate subunit vaccine confers protection against triplicate challenge by bacillus anthracis.
Schully KL; Sharma S; Peine KJ; Pesce J; Elberson MA; Fonseca ME; Prouty AM; Bell MG; Borteh H; Gallovic M; Bachelder EM; Keane-Myers A; Ainslie KM
Pharm Res; 2013 May; 30(5):1349-61. PubMed ID: 23354770
[TBL] [Abstract][Full Text] [Related]
35. Stochastic humoral immunity to Bacillus anthracis protective antigen: identification of anti-peptide IgG correlating with seroconversion to Lethal Toxin neutralization.
Dumas EK; Nguyen ML; Cox PM; Rodgers H; Peterson JL; James JA; Farris AD
Vaccine; 2013 Apr; 31(14):1856-63. PubMed ID: 23415781
[TBL] [Abstract][Full Text] [Related]
36. Nasal immunization with a dual antigen anthrax vaccine induced strong mucosal and systemic immune responses against toxins and bacilli.
Sloat BR; Cui Z
Vaccine; 2006 Sep; 24(40-41):6405-13. PubMed ID: 16828937
[TBL] [Abstract][Full Text] [Related]
37. Characterization of the human immune response to the UK anthrax vaccine.
Baillie L; Townend T; Walker N; Eriksson U; Williamson D
FEMS Immunol Med Microbiol; 2004 Oct; 42(2):267-70. PubMed ID: 15364114
[TBL] [Abstract][Full Text] [Related]
38. Mouse model characterisation for anthrax vaccine development: comparison of one inbred and one outbred mouse strain.
Flick-Smith HC; Waters EL; Walker NJ; Miller J; Stagg AJ; Green M; Williamson ED
Microb Pathog; 2005 Jan; 38(1):33-40. PubMed ID: 15652293
[TBL] [Abstract][Full Text] [Related]
39. Nasal immunization with anthrax protective antigen protein adjuvanted with polyriboinosinic-polyribocytidylic acid induced strong mucosal and systemic immunities.
Sloat BR; Cui Z
Pharm Res; 2006 Jun; 23(6):1217-26. PubMed ID: 16718616
[TBL] [Abstract][Full Text] [Related]
40. CD1d-dependent B-cell help by NK-like T cells leads to enhanced and sustained production of Bacillus anthracis lethal toxin-neutralizing antibodies.
Devera TS; Aye LM; Lang GA; Joshi SK; Ballard JD; Lang ML
Infect Immun; 2010 Apr; 78(4):1610-7. PubMed ID: 20123711
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
